Updated from 2:46 p.m. EST
were among the worst-performing health-related stocks Thursday after the company delayed the filing of its annual report because its audit committee needs more time to review issues related to the way the company accounts for product sales and returns.
Ligand said the review is expected to focus on the company's revenue recognition policies and practices for current as well as past reporting periods. The company is also reviewing the accounting and classification of its sales of royalty rights. The audit committee is working as quickly as possible to complete the review but Ligand said that it couldn't estimate when the 2004 audit will be completed.
As a result, Ligand has notified the
Securities and Exchange Commission
that its annual report will be delayed until the review is finished. Since the company has not sought a 15-day extension to file its 10-K, and because the company does not believe that it will be filed by March 31, Ligand is no longer in compliance with continued Nasdaq listing requirements, it said. The company plans to meet with a Nasdaq panel regarding its compliance with listing standards. Shares, which had fallen by almost 43% earlier in the trading session, traded down $1.12, or 12.6%, to $7.75.
( GLGC) fell 6% after the company said that it would post a 2005 loss that could be as high as $28 million. Gene Logic said that it expects to post a loss of $26 million to $28 million on sales of $83.5 million to $85.5 million. The company plans to invest about $14 million to develop its drug repositioning and selection business, an area of interest, the company said, for pharmaceutical customers. Despite the 2005 forecast, the company did say that it expects to post a profit during 2007 on sales that will exceed $100 million. Gene Logic expects to have about $70 million to $75 million in cash at the end of 2005 and expects to generate cash in 2007. Shares traded down 21 cents to $3.28.
fell 12.9% after the company said a federal magistrate issued a report late Wednesday recommending a denial of the company's motion to prevent the launch of generic forms of Periostat, the company's drug that is used as an adjunct to scaling and root planning for the treatment of adult periodontitis. The company has 10 days to file objections to the report. If a district court issues an order that backs the recommendation of the magistrate,
will be free to market and sell generic equivalents of Periostat. According to the company, Ivax and CorePharma have not yet indicated that they've received Food and Drug Administration approval. "The recommendation is obviously a disappointment to us," CollaGenex said. "We are studying the recommendation and considering all of our options." Shares traded down 69 cents to $4.68.
fell 3% after the specialty pharmaceutical company said that it plans to sell $125 million in convertible notes that mature in 2015. A portion of the proceeds will be used to buy up to $35 million of the company's stock, which will be done concurrently with the notes sale. The remaining proceeds will be used to fund general corporate purposes. Shares traded down 80 cents to $26.27.
Other health care movers included
, down 4 cents to $26.01;
, down 7 cents to $7.25;
, up 97 cents to $38.16;
, up 97 cents to $58.95;
( AMLN), up $1.23 to $20.76;
( DNA), down $1.49 to $52.89;
, up 2 cents to $31.72; and
Johnson & Johnson
, down 6 cents to $66.99.